Verified Nov 2026
Other
·
Parsippany-Troy Hills, New Jersey
·
Since 2022
Embecta is a medical device company headquartered in Parsippany-Troy Hills, New Jersey, United States, founded in 2022 and reported to employ between 1,000 and 5,000 people. It makes insulin delivery products, including pen needles, insulin syringes and safety injection devices, and serves the healthcare sector. The company became independent in April 2022 and is not publicly listed. In May 2026 it closed its acquisition of Owen Mumford, an auto-injector maker, for up to $201 million.
embecta at a glance
Revenue
$1-5B
Est. band
Employees
1,000-5,000
Founded
2022
Headquarters
Parsippany-Troy Hills, New Jersey
Certifications
ISO 13485 · ISO 14001
Import activity
200
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Consumer Goods
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
200
Named foreign suppliers
7
Top origins
Belgium · France · China · Ireland
Shared foreign counterparties do not establish that these companies buy from embecta.
What this tells a buyer
Customs records show 200 shipments, with suppliers located in Ireland, China, Mexico, Japan and the Netherlands.
The company holds ISO 13485 and ISO 14001 certifications and manufactures facilities in the United States, Ireland and China.
Its estimated annual revenue falls in the $1 billion to $5 billion range, and it has reported Honda as a customer.
Source: US customs bill-of-lading records and public filings · Last verified Nov 05, 2026
STABILITY SIGNALS
Operating
4 years in operation (founded 2022).
200 US import shipments on record.
Holds ISO 13485, ISO 14001 certification(s) per public sources.
Overview
Embecta is a medical device company headquartered in Parsippany-Troy Hills, New Jersey, United States, founded in 2022 and reported to employ between 1,000 and 5,000 people. It makes insulin delivery products, including pen needles, insulin syringes and safety injection devices, and serves the healthcare sector. The company became independent in April 2022 and is not publicly listed. In May 2026 it closed its acquisition of Owen Mumford, an auto-injector maker, for up to $201 million.
At a glance
Attribute | Detail |
|---|---|
Founded | 2022 |
Headquarters | Parsippany-Troy Hills, New Jersey |
Employees | 1,000-5,000 |
Revenue | $1-5B (estimated) |
Certifications | ISO 13485 · ISO 14001 |
What embecta makes
The company holds ISO 13485 and ISO 14001 certifications and manufactures facilities in the United States, Ireland and China.
Products and capabilities described on the company's own site include Emissions (source: embecta.com).
Certifications
embecta is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:
ISO 13485 — gimaitaly.com
ISO 14001 — embecta.com
Trade and customs footprint
Customs records show 200 shipments, with suppliers located in Ireland, China, Mexico, Japan and the Netherlands. US customs bill-of-lading records list 200 inbound shipments across 7 foreign suppliers, with top origins including Belgium · France · China · Ireland.
Known customers
The counterparties below come from public sources that state the relationship directly. A shared counterparty does not by itself establish a current buying relationship unless the source says so:
Honda — reported by embecta.com
Latest developments
2026-08-07 — Embecta Q3 FY2026 slides: earnings beat offsets revenue decline By Investing.com (investing.com)
2026-05-18 — Embecta closes Owen Mumford acquisition for up to $201M | MedTech Dive (medtechdive.com)
2026-03-19 — embecta Announces Definitive Agreement to Acquire Owen (globenewswire.com)
2026-03-19 — Embecta to buy auto-injector maker Owen Mumford for $200M to diversify beyond insulin (fiercebiotech.com)
2025-11-14 — embecta Announces Major Expansion of Partnership with Direct Relief to Enhance Global Access to Diabetes Care-VCBeat (vcbeathealth.com)
Facilities
embecta is headquartered in Parsippany-Troy Hills, New Jersey. Public sources also reference these locations:
Ireland — policyrisk.com
Company details
Its estimated annual revenue falls in the $1 billion to $5 billion range, and it has reported Honda as a customer. embecta was founded in 2022, has an estimated 1,000-5,000 employees, and is headquartered in Parsippany-Troy Hills, New Jersey. On the LightSource stability read it is rated "Operating": 4 years in operation (founded 2022). 200 US import shipments on record. Holds ISO 13485, ISO 14001 certification(s) per public sources.
Frequently asked questions
What does embecta do?
Embecta is a medical device company headquartered in Parsippany-Troy Hills, New Jersey, United States, founded in 2022 and reported to employ between 1,000 and 5,000 people. It makes insulin delivery products, including pen needles, insulin syringes and safety injection devices, and serves the healthcare sector. The company became independent in April 2022 and is not publicly listed. In May 2026 it closed its acquisition of Owen Mumford, an auto-injector maker, for up to $201 million.
Where is embecta headquartered?
embecta is headquartered in Parsippany-Troy Hills, New Jersey.
When was embecta founded?
embecta was founded in 2022.
How big is embecta?
embecta has an estimated 1,000-5,000 employees, with revenue in the $1-5B range (estimated).
What certifications does embecta hold?
embecta lists ISO 13485 · ISO 14001 on its website. Confirm the certified scope for the specific plant producing your part.
Does embecta import from overseas suppliers?
US customs bill-of-lading records show 200 inbound shipments for embecta, with top origins including Belgium · France · China · Ireland.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.